Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinantHSV-1

Journal of Investigative Dermatology

Volumn 129, Issue 10, 2009, Pages 2470-2479

  Brans, Richard ^a   Akhrameyeva, Natali V ^a   Yao, Feng ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN D; HERPES SIMPLEX VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; TH1 CELL; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE;

EID: 70349132325     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.86     Document Type: Article

References (43)

1. Augustinova H, Hoeller D, Yao F (2004) The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J Virol 78:5756-5765
2. Benedetti J, Corey L, Ashley R (1994) Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 121:847-854
3. Bernstein DI, Stanberry LR (1999) Herpes simplex virus vaccines. Vaccine 17:1681-1689
4. Bourne N, Milligan GN, Stanberry LR, Stegall R, Pyles RB (2005) Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 192:2117-2123
5. Bourne N, Stanberry LR, Bernstein DI, Lew D (1996) DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 173:800-807
6. Boursnell ME, Entwisle C, Blakeley D, Roberts C, Duncan IA, Chisholm SE et al. (1997) A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 175:16-25
7. Brans R, Eriksson E, Yao F (2008) Immunization with a dominant-negative herpes simplex virus (HSV) type 1 protects against HSV-1 skin disease in guinea pigs. J Invest Dermatol 128:2825-2832
8. Bryson Y, Dillon M, Bernstein DI, Radolf J, Zakowski P, Garratty E (1993) Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis 167:942-946
9. Corey L, Adams HG, Brown ZA, Holmes KK (1983) Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 98:958-972
10. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr et al. (1999) Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282:331-340
11. Da Costa XJ, Morrison LA, Knipe DM (2001) Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Virology 288:256-263
12. Dolan A, Jamieson FE, Cunningham C, Barnett BC, McGeoch DJ (1998) The genome sequence of herpes simplex virus type 2. J Virol 72: 2010-2021
13. Dudek T, Knipe DM (2006) Replication-defective viruses as vaccines and vaccine vectors. Virology 344:230-239
14. Erturk M, Welch MJ, Phillpotts RJ, Jennings R (1989) Protection and serum antibody responses in guinea-pigs and mice immunized with HSV-1 antigen preparations obtained using different detergents. Vaccine 7:431-436
15. Freeman EE, Orroth KK, White RG, Glynn JR, Bakker R, Boily MC et al. (2007) Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Transm Infect 83(Suppl 1):i17-24
16. Jin F, Prestage GP, Mao L, Kippax SC, Pell CM, Donovan B et al. (2006) Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the health in men study. J Infect Dis 194:561-570
17. Jones CA, Cunningham AL (2004) Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease. Herpes 11:12-17
18. Koelle DM, Corey L (2003) Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 16:96-113
19. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L (1987) Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 316: 1444-1449
20. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE (1999) A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 341:1432-1438
21. Lekstrom-Himes JA, Pesnicak L, Straus SE (1998) The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. J Virol 72:2760-2764
22. Liesegang TJ (1991) A community study of ocular herpes simplex. Curr Eye Res 10(Suppl):111-5
23. Looker KJ, Garnett GP (2005) A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect 81:103-107
24. Lu Z, Brans R, Akhrameyeva NV, Murakami N, Xu X, Yao F (2009) High-level expression of glycoprotein D by a dominant-negative HSV-1 augments its efficacy as a vaccine against HSV-1 infection. J Invest Dermatol 129:1174-1184
25. McGeoch DJ, Dalrymple MA, Davison AJ, Dolan A, Frame MC, McNab D et al. (1988) The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol 69(Part 7):1531-1574
26. McLean CS, Erturk M, Jennings R, Challanain DN, Minson AC, Duncan I et al. (1994) Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 170:1100-1109
27. Mertz KJ, Trees D, Levine WC, Lewis JS, Litchfield B, Pettus KS et al. (1998) Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 178:1795-1798
28. Morrison LA, Knipe DM (1994) Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 68:689-696
29. Nguyen LH, Knipe DM, Finberg RW (1992) Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol 66:7067-7072
30. Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM (2007) Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect 83:16-22
31. Roberts C (2005) Genital herpes in young adults: changing sexual behaviours, epidemiology and management. Herpes 12:10-14
32. Sawtell NM (1998) The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol 72:6888-6892
33. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG (1987) Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 155:914-920
34. Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY et al. (2000) Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 30:549-566
35. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S et al. (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347:1652-1661
36. Wald A, Link K (2002) Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185:45-52
37. Whitley RJ (2006) Herpes simplex encephalitis: adolescents and adults. Antiviral Res 71:141-148
38. Whitley RJ, Roizman B (2001) Herpes simplex virus infections. Lancet 357:1513-1518
39. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ et al. (2006) Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-973
40. Yao F, Eriksson E (1999) A novel anti-herpes simplex virus type 1-specific herpes simplex virus type 1 recombinant. Hum Gene Ther 10:1811-1818
41. Yao F, Eriksson E (2002) Inhibition of herpes simplex virus type 2 (HSV-2) viral replication by the dominant negative mutant polypeptide of HSV-1 origin binding protein. Antiviral Res 53:127-133
42. Yao F, Schaffer PA (1995) An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J Virol 69:6249-6258
43. Yao F, Theopold C, Hoeller D, Bleiziffer O, Lu Z (2006) Highly efficient regulation of gene expression by tetracycline in a replication-defective herpes simplex viral vector. Mol Ther 13:1133-1141